Share Name Share Symbol Market Type Share ISIN Share Description
Hikma Pharmaceuticals LSE:HIK London Ordinary Share GB00B0LCW083 ORD SHS 10P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -9.00p -0.46% 1,929.00p 1,925.00p 1,926.00p 1,932.00p 1,914.00p 1,932.00p 612,677.00 16:35:09
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 977.3 215.8 85.9 19.1 4,641.72

Hikma Pharmaceuticals (HIK) Latest News

More Hikma Pharmaceuticals News
Hikma Pharmaceuticals Takeover Rumours

Hikma Pharmaceuticals (HIK) Share Charts

1 Year Hikma Pharmaceuticals Chart

1 Year Hikma Pharmaceuticals Chart

1 Month Hikma Pharmaceuticals Chart

1 Month Hikma Pharmaceuticals Chart

Intraday Hikma Pharmaceuticals Chart

Intraday Hikma Pharmaceuticals Chart

Hikma Pharmaceuticals (HIK) Discussions and Chat

Hikma Pharmaceuticals Forums and Chat

Date Time Title Posts
23/1/201721:33Hikma Pharmaceuticals404.00
13/1/201515:12 *** Hikma ***98.00

Add a New Thread

Hikma Pharmaceuticals (HIK) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
23/01/2017 17:11:401,923.8397018,661.14O
23/01/2017 17:08:061,922.00357.66NT
23/01/2017 17:06:561,925.191633,138.06NT
23/01/2017 17:04:551,931.1450965.57NT
23/01/2017 17:04:551,931.151292,491.18NT
View all Hikma Pharmaceuticals trades in real-time

Hikma Pharmaceuticals (HIK) Top Chat Posts

Hikma Pharmaceuticals Daily Update: Hikma Pharmaceuticals is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker HIK. The last closing price for Hikma Pharmaceuticals was 1,938p.
Hikma Pharmaceuticals has a 4 week average price of 1,902.82p and a 12 week average price of 1,768.67p.
The 1 year high share price is 2,703p while the 1 year low share price is currently 1,575p.
There are currently 240,628,077 shares in issue and the average daily traded volume is 643,147 shares. The market capitalisation of Hikma Pharmaceuticals is £4,641,715,605.33.
broadwood: Quite why the share price fell so much was very surprising to me. Probably over the worst and strength returning.
broadwood: Numis has upgraded its recommendation on Hikma Pharmaceuticals [LON:HIK] to 'buy' from 'hold' ahead next week's third quarter update and following a 35 per cent decline in the share price over the past three months. The broker pointed out that the shares have significantly underperformed the UK Mid-Cap Healthcare and Global Specialty Pharma sectors but sees the Q3 results on 10th November and the "Meet the Management" event on 15th November as the catalysts for a re-rating. Analyst have set a new target price of 2,350 pence per share
sandeep67: 3 directors spent millions on shares each yesterday. Looks like Institutions want in by dropping the price to encourage scared selling. Can't see why the share price is inversing against the huge guys
broadwood: Jordanian drugs-maker Hikma became the fourth pharma constituent of the FTSE 100 in March 2015, before falling out of favour with investors and dropping out of the top index a year later. But a recent positive trading statement has seen the share price rally enormously and last month the group rejoined the FTSE 100 having replaced satellite firm Insmarsat.
broadwood: That's a pretty big commitment in anyones book. Share price continues to recover and this news certainly helps.
r ball: If you wait for a pullback it never happens. buy and strength and increase holding as share price rises.
broadwood: Hikma Pharmaceuticals Medicines play Hikma Pharmaceuticals (LSE: HIK) was also forced onto the back foot last week, the stock conceding 3% during the five-day trading period. In total the business has seen its share price fall an eye-popping 18% during the corresponding point in September, but I believe this weakness represents a terrific bargain-hunting opportunity. Hikma is clearly on a strong upward trajectory thanks to the galloping popularity of its Branded and Injectables division, while recent acquisitions in the UK and US have significantly boosted its product suite and development pipeline. On top of this, the firm is doubling-down on its operations in critical emerging markets, exemplified by its licensing deal with over-the-counter giant Vitabiotics in August to sell its labels in the Middle East and North Africa. I fully expect revenues at Hikma to explode as we look down the line.
broadwood: Jefferies ups Hikma to 'buy', says Roxane deal is a 'game changer' (ShareCast News) - Hikma Pharmaceuticals got a boost after Jefferies upgraded the stock to 'buy' from 'hold' and raised its price target to 2,615p from 2,134p as it integrates the company's "transformational" deal with Roxane Laboratories. "In our view Hikma is transitioning to a period of remarkable growth as it executes on recent acquisitions and we expect share price momentum to continue despite the 12% rally," it said, adding that Hikma is now its preferred name in the EMEA generics sector. Jefferies said the acquisition of Roxane, at $2.65bn, is a game-changer for Hikma in the US and provides a platform and pipeline to grow its business with opportunities to create further value from potential synergies and diversify its revenue base. It noted that Roxane has 88 differentiated products across specialised segments which are highly complementary to Hikma's existing US business. The combination will create the number 6 player in the US generics market, from 20 previously, said Jefferies. It raised its 2016 earnings per share estimate by 4% and 2017 by 14%, saying it believes the integration of Roxane combined with solid market fundamentals should improve Hikma's earnings power despite higher interest charges and equity dilution to shareholders.
jeffcranbounre: Hikma is featured into today's ADFVN podcast. To listen to the podcast click here> In today's podcast: - Technical Analyst Nicola Duke will be chatting and charting, Anite, Big Yellow Group, ITE, Union Jack Oil, Afren. Nicola on Twitter is @NicTrades - And the micro and macro news including: Quindell #QPP Afren #AFR Shire #SHP ITV #ITV Taylor Wimpey #TW. Big Yellow Group #BYG ITE #ITE Union Jack Oil #UJO Anite #AIE Unite Group #UTG Pace #PIC Royal Mail #RMG Prudential #PRU Hikma Pharmaceuticals #HIK AO World #AO. Betfair #BET Sound Oil #SOU Advanced Oncotherapy #AVO International Airlines Group #IAG Afren #AFR Ophir Energy #OPHR Premier Farnell #PFL New River Retail #NRR Victrex #VCT Catlin Group #CGL Every Tuesday is Ten Bagger Tuesday on the podcast. If you know of a stock, whose share price has the potential to increase ten fold, just click the link below. Ten Bagger Tuesday (All it involves is filling out a form that will take you around 5 minutes and you don't personally appear on the podcast). Once a week, on a Friday, I feature a tip from a listener to this podcast, if you'd like to suggest a stock click the link below: Suggest a stock (Again all it involves is filling out a form that will take you around 5 minutes and you don't personally appear on the podcast). You can subscribe to this podcast in iTunes by clicking HERE To follow me on Twitter click HERE As a listener to the ADVFN podcast you can take advantage of some exclusive first year discounts on popular subscriptions: Bronze - £50 (normally £73.82/year) Silver - £145 (normally £173.71/year) Level 2 - £350 (normally £472.94/year) Call 0207 0700 961 and ask for the ADVFN Podcast discount to take advantage of these reduced rates or just CLICK HERE for more information. Please DO NOT buy any stock recommended in this podcast basely solely on what you hear. The opinions in this podcasts are just that, opinions. Please do you own research before investing. Justin    
broadwood: Hikma Pharmaceuticals Hikma Pharmaceuticals was founded in 1978, and floated on the London stock exchange in 2005 with a market capitalisation of £480m. In less than 10 years, Hikma has grown into a £3.9bn company and is now poised just below the threshold for entry into the FTSE 100. Hikma operates through three businesses (branded, generics and injectables) and is a market leader in the Middle East and North Africa (MENA) region. Hikma trades on a deserved premium P/E of 22 at a share price of 1,964p, and has the financial resources to make strategic acquisitions and investments that could rapidly lift the company into the FTSE 100. Hikma’s strong position in the MENA region also makes the company attractive to US and European drugs players. A bid (or rumours of one) could be another catalyst for catapulting Hikma’s valuation through the FTSE 100 entry level.
Hikma Pharmaceuticals share price data is direct from the London Stock Exchange
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:41 V: D:20170124 03:09:15